Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 10,881–10,900 of 17,974 drug recalls

Drug Recall Terminated Historical recordClass III

Isopto Carpine (pilocarpine hydrochloride opthalmic solution) 4%, packaged in 15 mL bottle, Rx only, Manufactured by: Alcon Laboratories, Inc. Fort Worth Texas 76134 USA NDC 0998-0206-15

by Novartis Pharmaceuticals Corp.

Reason
Failed Impurities/Degradation Specifications.
Recall initiated
March 22, 2017
Reported by FDA
May 3, 2017
Distribution
nationwide

View recall →

Drug Recall Terminated Historical recordClass II

hCG Body Shaper, Highly Purified Human Chorionic Gonadotrophin 5000 IU, Colloidal Silver B12, Stabilizers/Excipients, Not For Medical Use, Must Be Refrigerated, Distributed by HCG Body Shaper, St. Peters, MO

by Gary Wood

Reason
Marketed without an Approved NDA/ANDA; FDA analysis has found the product to be tainted with human chorionic gonadotropin, rendering it an unapproved drug
Recall initiated
March 28, 2017
Reported by FDA
May 3, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Nystatin and Triamcinolone Acetonide Cream, USP, 100,000 USP nystatin units and 1 mg triamcinolone acetonide, distributed in a) 15 grams (NDC 51672-1263-1), b) 30 grams (NDC 51672-1263-2) and c) 60 grams (NDC 51672-1263-3) tubes, Rx only, TARO label; Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1 -- Dist. by: Taro Pharmaceuticals U.S.A. Inc., Hawthorne, NY 10532

by Taro Pharmaceuticals U.S.A., Inc.

Reason
Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability
Recall initiated
March 28, 2017
Reported by FDA
April 26, 2017
Distribution
Nationwide and Puerto Rico

View recall →

Drug Recall Terminated Historical recordClass III

Dye Free Allergy Softgel Gelatin Capsule, 15,000-count bulk drums, aenova/Swiss Caps USA, Inc., 14193 S.W. 119th Avenue, Miami, FL 33186, Product Code MSU0067P, NDC 6897080284

by InnovaGel

Reason
Subpotent
Recall initiated
January 5, 2017
Reported by FDA
April 26, 2017
Distribution
NY only

View recall →

Drug Recall Terminated Historical recordClass III

Diphenhydramine HCl 25 mg, Softgel Gelatin Capsule, 15,000-count bulk drums, aenova/Swiss Caps USA, Inc., 14193 S.W. 119th Avenue, Miami, FL 33186, Product Code MSU0048P, NDC 6897080284

by InnovaGel

Reason
Subpotent
Recall initiated
January 5, 2017
Reported by FDA
April 26, 2017
Distribution
NY only

View recall →

Drug Recall Terminated Historical recordClass III

CLENZIderm M.D. Acne Treatment System, kit has 3 bottles a) Therapeutic Lotion (benzoyl peroxide 5% Acne Treatment) 47mL bottle, b) Daily Care Foaming Cleanser (Salicylic Acid 2% Acne Treatment) 118 mL bottle, c) Salicylic Acid 2% Acne Treatment 148mL, Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc Long Beach, CA 90806 Made in USA, Product SKU 301876103018, NDC 0187-6103-01

by Valeant Pharmaceuticals North America LLC

Reason
Discoloration.
Recall initiated
March 20, 2017
Reported by FDA
April 26, 2017
Distribution
nationwide

View recall →

Drug Recall Terminated Historical recordClass III

CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc Long Beach, CA 90806 Made in USA. Product SKU 301876102042, NDC 0187-6102-04

by Valeant Pharmaceuticals North America LLC

Reason
Discoloration.
Recall initiated
March 20, 2017
Reported by FDA
April 26, 2017
Distribution
nationwide

View recall →

Drug Recall Terminated Historical recordClass III

BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, packaged in a) 60-count bottles (NDC 59746-317-60) and b) 100-count bottles (NDC 59746-317-01), Rx only, Manufactured by: Julibant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.

by Jubilant Cadista Pharmaceuticals, Inc.

Reason
Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.
Recall initiated
April 8, 2016
Reported by FDA
April 19, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass III

BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 150 mg, packaged in a) 60-count bottles (NDC 59746-316-60) and b) 100-count bottles (NDC 59746-316-01), Rx only, Manufactured by: Julibant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.

by Jubilant Cadista Pharmaceuticals, Inc.

Reason
Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.
Recall initiated
April 8, 2016
Reported by FDA
April 19, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass III

BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 100 mg, packaged in a) 60-count bottles (NDC 59746-315-60) and b) 100-count bottles (NDC 59746-315-01), Rx only, Manufactured by: Julibant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.

by Jubilant Cadista Pharmaceuticals, Inc.

Reason
Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.
Recall initiated
April 8, 2016
Reported by FDA
April 19, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

hydrALAZINE HYDROCHLORIDE INJECTION, USP, 20 mg/mL, 1 mL Single Dose Vial, packaged in 25 Vials per carton, Rx only, APP Fresenius Kabi USA, LLC, Lake Surich, IL 60047, NDC 63323-614-01, Distributed by McKesson Medical-Surgical, Inc.

by Mckesson Medical Surgical

Reason
Temperature Abuse: Certain pieces of these lots distributed by McKesson Medical Surgical Inc. were inadvertently stored refrigerated rather than the labeled room temperature recommendation.
Recall initiated
March 8, 2017
Reported by FDA
April 19, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass III

Lumigan (bimatoprost ophthalmic solution) 0.01%, 7.5 mL bottle, Rx only, Allergan Irvine, CA 92612, NDC 0023-3205-08.

by Allergan Sales, LLC

Reason
Failed Impurities/Degradation Specifications
Recall initiated
March 16, 2017
Reported by FDA
April 19, 2017
Distribution
Nationwide in the US

View recall →

Drug Recall Terminated Historical recordClass II

ESTRADIOL, USP Bulk (Hemihydrate), in a) 25 g (NDC 38779-2261-04) and b) 100 g (NDC 38779-2261-05) bottles, Packed by MEDISCA INC. PLATTSBURGH, NY Product Code 2261

by Medisca, Inc.

Reason
cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection
Recall initiated
April 3, 2017
Reported by FDA
April 19, 2017
Distribution
Nationwide, Australia, Bahamas, Italy, Singapore, Thailand, United Kingdom

View recall →

Drug Recall Terminated Historical recordClass II

ESTRADIOL, USP (Hemihydrate)(Micronized), in a) 100 mg (NDC 38779-0869-07), b) 1 g (NDC 38779-0869-06), c) 5 g (NDC 38779-0869-03), d) 10 g (NDC 38779-0869-01), e) 25 g (NDC 38779-0869-04), f) 100 g (NDC 38779-0869-05) , g) 500 g (NDC 38779-0869-08), h) 1 Kg (NDC 38779-0869-09) bottles, Packed by MEDISCA INC. PLATTSBURGH, NY 12901; Product Code 0869

by Medisca, Inc.

Reason
cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection
Recall initiated
April 3, 2017
Reported by FDA
April 19, 2017
Distribution
Nationwide, Australia, Bahamas, Italy, Singapore, Thailand, United Kingdom

View recall →

Drug Recall Terminated Historical recordClass II

ESTRONE, USP Bulk, in a) 100 mgs (NDC 38779-0891-05), b) 1 gram (NDC 38779-0891-06), c) 5 grams (NDC 38779-0891-03), d) 25 grams (NDC 38779-0891-04), and e) 100 grams (NDC 38779-0891-09) Bottles, Packed by MEDISCA INC. PLATTSBURGH, NY 12901; Product Code 0891

by Medisca, Inc.

Reason
cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection
Recall initiated
April 3, 2017
Reported by FDA
April 19, 2017
Distribution
Nationwide, Australia, Bahamas, Italy, Singapore, Thailand, United Kingdom

View recall →

Drug Recall Terminated Historical recordClass II

ESTRIOL, USP (Micronized) Bulk, in a) 5 grams (NDC 38779-0732-03), b) 25 grams (NDC 38779-0732-04) , c) 100 grams (NDC 38779-0732-05), and d) 1 Kg (NDC 38779-0732-09) bottles, Packed by MEDISCA, INC. PLATTSBURGH, NY 12901; Product Code 0732

by Medisca, Inc.

Reason
cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection
Recall initiated
April 3, 2017
Reported by FDA
April 19, 2017
Distribution
Nationwide, Australia, Bahamas, Italy, Singapore, Thailand, United Kingdom

View recall →

Drug Recall Ongoing Historical recordClass II

Double Hyaluronic 1000, 'AN OUNCE OF GOLD' Volumizing Day Cream, Broad Spectrum SPF 30+, (Octinoxate 7.725%, Oxybenzone 6.18%, Octisalate 5.15%, Avobenzone 3.09%), Net Wt. 1.8 oz. (51 g) jar, Distributed by Signature Club A, Ltd, Tampa, FL 33609.

by Signature Club A Ltd

Reason
Microbial Contamination of Non-Sterile Products: odor complaint of product due to microbial contamination.
Recall initiated
March 1, 2017
Reported by FDA
April 19, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

LATANOPROST OPHTHALMIC SOLUTION, 0.005%, 125 ug/2.5 mL, packaged in 2.5 mL bottle, Rx only, Manufactured for: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-625-12

by Akorn, Inc.

Reason
Lack of assurance of sterility: product was found to be empty, under-filled, or leaking.
Recall initiated
March 17, 2017
Reported by FDA
April 19, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Levonorgestrel Non-Micronized, USP, Bulk, Rx only, For Prescription Compounding, Manufactured by Qinhuangdao Zizhu Pharmaceutical Co., Ltd., Qinhuangdao 066004, China (NDC 44132-012-01),

by Qinhuangdao Zizhu Pharmaceutical, Co.

Reason
cGMP Deviations; lack of quality assurance.
Recall initiated
March 24, 2017
Reported by FDA
April 19, 2017
Distribution
Product distributed to NY, TX, SC, CO, MN and NJ

View recall →

Drug Recall Terminated Historical recordClass II

Ethinyl Estradiol Micronized, USP, Bulk, Rx only, For Prescription Compounding, Manufactured by Qinhuangdao Zizhu Pharmaceutical Co., Ltd, Qinhuangdao 066004, China (NDC 44132-002-05)

by Qinhuangdao Zizhu Pharmaceutical, Co.

Reason
cGMP Deviations; lack of quality assurance.
Recall initiated
March 24, 2017
Reported by FDA
April 19, 2017
Distribution
Product distributed to NY, TX, SC, CO, MN and NJ

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.